Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three phase 3 ...

Kerik didn't file background report when he took NYPD post, city says United pilots endorse tentative agreement Suspect in fetus theft headed back to Missouri Despite death sentence, Peterson said to ...